Presently, Over 150 Neoantigen Targeted Therapies


Presently, over 150 neoantigen targeted therapies

The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.


To order this 320+ page report, which features 110+ figures and 140+ tables, please visit this link  


The USD 3 billion (by 2030) financial opportunity within the neoantigens market has been analyzed across the following segments:

  • Type of target disease indication
  • Bone cancer
  • Colorectal cancer
  • Gynecological cancer
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Other cancers


  • Type of neoantigens
  • Personalized neoantigens
  • Off-the-shelf neoantigens


  • Type of immunotherapy
  • Dendritic cell vaccines
  • DNA / RNA-based vaccines
  • Protein / peptide-based vaccines
  • TIL-based therapies


  • Route of administration
  • Intradermal
  • Intravenous
  • Subcutaneous
  • Other routes


  • Key geographical regions
  • North America
  • Europe
  • Rest of the World


The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:

  • Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
  • Ella Sorani (Vice President Research and Development, BioLineRx)
  • Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)


The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain:

  • Bavarian Nordic
  • Genocea Biosciences

Press Release: Variation 3 (Format 4)


  • Gradalis
  • Immunicum
  • Immunovative Therapies
  • Iovance Biotherapeutics
  • Medigene
  • Neon Therapeutics
  • Precision Biologics
  • Vaxon Biotech


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction


  1. Market Overview

  2. Company Profiles: Neoantigen Targeted Therapies

  3. Publication Analysis

  4. Patent Analysis

  5. Partnerships and Collaborations

  6. Funding and Investment Analysis

  7. Market Forecast and Opportunity Analysis

  8. Concluding Remarks

  9. Executive Insights

  10. Appendix 1: Tabulated Data

  11. Appendix 2: List of Companies and Organizations


To purchase a copy, please visit


Contact Details:

Gaurav Chaudhary

+1 (415) 800 3415


Keywords: predicts roots analysis


Other related blogs

The “Prefilled Syringe Fill / Finish Service Providers, 2020-2030” report features an extensive study of the current market

By : Roots Analysis

Key Inclusions A detailed review of the overall landscape of companies offering contract fill / f..

The prefilled syringe fill / finish services market is projected to grow at an annualized rate of over 10%, till 2030

By : Roots Analysis

Roots Analysis has done a detailed study on Prefilled Syringe Fill / Finish Services Market, 2020-20..

The prefilled syringe fill / finish services market is estimated to is estimated to reach close to USD 3 Billion by 2030

By : Roots Analysis

The numerous benefits offered by prefilled syringes, coupled to the growing self-medication trend, h..